Companies · Pharmaceuticals

Med-Tech Investments Group, LLC

CHICAGO · Pharmaceuticals

Diligence memoA one-page analyst read on Med-Tech Investments Group, LLC — recommendation, valuation, rhythm, risks.
$2.6M
Total raised · real
1
Rounds
0.4×
Latest step-up
Top 70%
Sector rank · raised
Seed
Latest stage · inferred · Sat Jan 28 2017 00:00:00 GMT+0000 (Coordinated Universal Time)

Med-Tech Investments Group, LLC looks over-valued against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the pharma sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Over-valued
  • Modeled value is 1.64× the median modeled value of Seed Pharmaceuticals companies in 2016–2018 (71 peers) — value vs value, same stage and era.
  • Issuer reports no revenue, yet is modeled well above niche peers.
Dormant
  • Last raise 9.4 yr ago; this sector typically re-raises about every 13 months.
  • Only one round on record and long silent — often defunct, acquired, or gone quiet.

Procedural diagnosis est. — rule-based common-sense checks over the filing pattern, issuer name, activity cadence, and surfaced operating evidence.

Issuer-vehicle patternmedium confidence

Med-Tech Investments Group, LLC behaves more like a recurring private-offering issuer than a conventional venture-backed operating company.

Issuer structure
Company-like
No recurring-offering pattern strong enough to override normal financing interpretation.
Lifecycle
9.4 yr record
Peak capital year was 2017 with $3.6M across 2 filings.
Market position
ahead of 31% of Pharmaceuticals peers
Capital scale is ahead of 31% of Pharmaceuticals peers; modeled value is above 55% of peers by modeled value. Large capital with mid-pack modeled value can signal an issuer/program profile rather than operating-company growth.
Valuation reliability
Normal applicability
Stage/dilution valuation models are weakest when the issuer is broad-sector, recurring, or vehicle-like.
Operating evidence
Sparse
No clear CEO/founder/principal role is surfaced, so operating-company confidence is lower.
Data quality
Needs review
Row-level filing totals differ from canonical totals, so amendment/superseded filtering should be checked.
What triggered this
  • Legal name looks like an issuer vehicle rather than a product company.
  • No clearly named CEO/founder/principal role in the public records surfaced here.
  • No verified homepage on the profile yet.
  • Capital program peaked in 2017: $3.6M across 2 filings.
  • Largest single filing was $2.6M on 2017-01-28.
  • Filing rows sum to $3.6M, while canonical raised total is $2.6M; likely amendments/superseded rows are mixed into the detail view.
How to read the page
  • Read this less like a startup funding journey and more like a capital-raising program.
  • Stage-based valuation and peer labels have lower applicability for this pattern.
  • The more important signal is lifecycle: repeated filings ended years ago, so current activity needs outside confirmation.
  • Canonical filtering should be tightened before using row-level totals for diligence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Pharmaceuticals

Med-Tech Investments Group, LLC is one of 1613 Pharmaceuticals companies tracked from CHICAGO. By capital raised it ranks in the long tail (ahead of 31% of sector peers), and mid-pack by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
No revenue
Issuer revenue
Rule 506(b)
Reg D exemption
4
Investors (latest)
2015
Year incorporated
2017-01-28
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$25M$50M$75M$100MSeed · 2017-01-28 Raised $2.6M (real) Modeled valuation $99M (est)$2.6M$99MSeed2017Seed · 2017-01-28 Raised $1.0M (real) Modeled valuation $40M (est)$1.0M$40MSeed2017+$1.0MCumulative $3.6M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Seed$2.6M · 2017
Seed extension$1.0M · 2017

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 50%.

Modeled valuation trajectory
$98.9M
Base estimate est.
$2.0M
Conservative case
$776.0M
Upside case
$13.0M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Seeda $1.0M–$4.0M round). Valuation is modeled from stage benchmarks scaled by the pharma sector profile. Directional, not a quoted figure.

Seed · modeled $98.9M · 2017-01-282017Seed · modeled $39.6M · 2017-01-282017
Model inputs · modeled:benchmark-stage-stepup-v1
20%
Dilution assumption
Implied ownership sold in the financing.
34%
Survival probability
15% low · 52% high
1.68×/yr
Annual markup
2.20×/yr upside case
6.0 yr
Elapsed time used
9.4 yr actual, capped for stale marks
pharma
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
0 mo
Avg between rounds
Capital velocity
9.4 yr
On record since
2017
First round
2
Rounds on file
How it compares to the market

Benchmarked against 1613 companies in Pharmaceuticals. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 0.3× of median
This company$2.6M
Sector median$8.1M
Latest round — vs other Seed rounds in sector (real $, this stage) 0.6× of median
This company$1.0M
Sector median$1.7M
Modeled value — vs sector median (estimate, all stages) 1.3× above median
This company$98.9M
Sector median$76.1M

Raised more than 31% of sector peers (real $). Modeled value above 55% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Seed) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #23 of 71.

This companyCohort peer
$10.0M$100.0M$1.0B$1.0M$10.0MCapital raised (log)Chase Therapeutics Corp · Seed Raised $5.3M · modeled $152.2M (est)Acura Pharmaceuticals, Inc · Seed Raised $4.0M · modeled $152.2M (est)Paragon Biosciences Skyline Capital, LLC · Seed Raised $4.0M · modeled $150.9M (est)Phoenix PharmaLabs Inc · Seed Raised $3.5M · modeled $133.1M (est)Saghmos Therapeutics, Inc. · Seed Raised $3.5M · modeled $133.1M (est)Immucell Corp /De/ · Seed Raised $3.5M · modeled $131.8M (est)Madrigal Pharmaceuticals, Inc. · Seed Raised $3.4M · modeled $128.4M (est)Hydropothecary Corp · Seed Raised $3.3M · modeled $124.6M (est)SapVax, LLC · Seed Raised $3.3M · modeled $123.6M (est)VersaPeutics, Inc. · Seed Raised $3.8M · modeled $121.7M (est)Westwood Life Sciences, Llc · Seed Raised $3.1M · modeled $116.3M (est)Har-Kcy, Llc · Seed Raised $3.0M · modeled $114.3M (est)Med-Tech Investments Group, LLC (this company) Raised $2.6M · modeled $98.9M (est)Med-Tech Investments Group, LLC
CompanyStageRaised · realValue · estvs peer med.
Chase Therapeutics CorpSeed$5.3M$152.2M2.52×
Acura Pharmaceuticals, IncSeed$4.0M$152.2M2.52×
Paragon Biosciences Skyline Capital, LLCSeed$4.0M$150.9M2.50×
Phoenix PharmaLabs IncSeed$3.5M$133.1M2.21×
Saghmos Therapeutics, Inc.Seed$3.5M$133.1M2.21×
Immucell Corp /De/Seed$3.5M$131.8M2.19×
Madrigal Pharmaceuticals, Inc.Seed$3.4M$128.4M2.13×
Hydropothecary CorpSeed$3.3M$124.6M2.07×
SapVax, LLCSeed$3.3M$123.6M2.05×
VersaPeutics, Inc.Seed$3.8M$121.7M2.02×
Westwood Life Sciences, LlcSeed$3.1M$116.3M1.93×
Har-Kcy, LlcSeed$3.0M$114.3M1.90×
Med-Tech Investments Group, LLC this companySeed$2.6M$98.9M1.64×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Seed$2.6M2017-01-28$13.0M$98.9M90%
Seed$1.0M2017-01-28$5.2M$39.6M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Seed$2.6M2017-01-28
    • First recorded raise — entered as Seed.
    • 18 investors on this round.
  2. Seed$1.0M2017-01-28
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 2.5× smaller than the prior — bridge or down round.
    • 4 investors on this round.
Intelligence
Modeled next raise
$1.0M
Modeled next size est.range $1.0M$1.7M
0.4×
Last step-up
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
R K Ahuja3 other2017-01
Registry & provenance

Med-Tech Investments Group, LLC is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1700916
SEC CIK
2015
Incorporated
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Westwood Life Sciences, LlcPharmaceuticalsSeed$3.1M$116.3Mnetwork1 shared operator · same sector · same stage
Tesla Life Sciences, LLCPharmaceuticalsSeed$11.2M$113.7Mnetwork1 shared operator · same sector · same stage
Koutif Therapeutics, LLCPharmaceuticalsSeed$2.6M$98.9Msame sector · same stage
Anthill Technologies IncPharmaceuticalsSeed$2.6M$97.6Msame sector · same stage
Fiorello Pharmaceuticals, Inc.PharmaceuticalsSeed$2.5M$97.0Msame sector · same stage
Cequent Pharmaceuticals IncPharmaceuticalsSeed$2.7M$100.9Msame sector · same stage
Laurent Pharmaceuticals Inc.PharmaceuticalsSeed$2.5M$53.8Msame sector · same stage
ImmunoRx Pharma, Inc.PharmaceuticalsSeed$2.7M$82.2Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
TF Tech Ventures, Inc.PharmaceuticalsPre-Seed$8.3M87%
MedAvail Holdings, Inc.PharmaceuticalsSeries B$679.3M87%
Shuttle Pharmaceuticals Holdings, Inc.PharmaceuticalsSeries A$7.1M85%
Cambridge Therapeutic Technologies, LLCPharmaceuticalsSeries A$185.8M84%
Cutispharma Holdings, Inc.PharmaceuticalsSeries C$2.5B84%
LP Investors, LLCPharmaceuticalsSeries B$1.4B84%
Bell Pharmacy Holdings, LLCPharmaceuticalsPre-Seed$2.2M84%
Xynomic Pharmaceuticals Holdings, Inc.PharmaceuticalsSeries A$464.6M83%
Frequently asked
How much funding has Med-Tech Investments Group, LLC raised?
Med-Tech Investments Group, LLC has raised approximately $2.6M in disclosed capital across 1 recorded financing round, aggregated from public filings.
What is Med-Tech Investments Group, LLC's estimated valuation?
Provath's modeled valuation for Med-Tech Investments Group, LLC is approximately $98.9M (modeled range $2.0M–$776.0M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Med-Tech Investments Group, LLC at?
Med-Tech Investments Group, LLC's latest modeled financing stage is Seed. Its most recent recorded round closed around Sat Jan 28.
What does Med-Tech Investments Group, LLC do and where is it based?
Med-Tech Investments Group, LLC operates in the Pharmaceuticals sector, based in CHICAGO.
Explore related

See where Med-Tech Investments Group, LLC sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Med-Tech Investments Group, LLC, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.